Conquering Diseases

A Study Looking At A New Drug For Treatment Of Stroke In Addition To Standard Treatments (Fastest)


Seeking men and women 18 years of age or older who have had a stroke caused by bleeding in their brain to help determine is a new drug called recombinant factor VIIa (rFVIIa) can improve outcomes compared to a placebo when added to the standard care provided after a stroke.


This study is being conducted to see if a medicine used to treat and prevent bleeding improves outcomes after a stroke caused by bleeding in the brain. The medicine is called Recombinant Factor VIIa (rFVIIa). Participants in this study will receive either the medicine or a placebo that contains no active medications.

What we're hoping for

To determine if treatment with Recombinant Factor VIIa (rFVIIa) works better than a placebo to improve participants outcome after a stroke

Additional Information Identifier: NCT03496883

 Principal Investigator

Adalia  Jun-O'Connell, MD

UMass Chan Medical School

 Study Contact

Beshoy  Armanios


UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655